Financials in USD. Standardized financial statements.
A compact view of how Korro Bio, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.39M | $2.27M | $0 | $0 | $14.07M | $36.98M | $28.95M | $0 | $0 |
| Revenue Growth? | +181.5% | 0.0% | 0.0% | -100.0% | -62.0% | +27.8% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $4.28M | $0 | $0 | $0 | $3.84M | $1.58M | $16.81M | $654,000 | $531,000 |
| Gross Profit? | $2.11M | $2.27M | $0 | $0 | $10.23M | $35.40M | $12.13M | -$654,000 | -$531,000 |
| Gross Margin? | +33.0% | +100.0% | 0.0% | 0.0% | +72.7% | +95.7% | +41.9% | 0.0% | 0.0% |
| Operating Expenses? | $89.45M | $94.18M | $84.53M | $59.00M | $94.26M | $62.95M | $32.81M | $18.29M | $15.78M |
| Operating Income? | -$87.34M | -$91.91M | -$84.53M | -$59.00M | -$84.03M | -$27.55M | -$20.68M | -$18.94M | -$16.31M |
| EBITDA? | -$83.06M | -$88.34M | -$80.90M | -$56.49M | -$80.07M | -$24.90M | -$17.93M | -$18.41M | -$19.53M |
| Income Before Tax | -$116.62M | -$83.44M | -$81.14M | -$58.02M | -$84.67M | -$26.48M | -$18.75M | -$19.17M | -$20.24M |
| Income Tax Expense | $637,000 | $141,000 | $27,000 | $10,000 | $15,000 | $35,000 | $0 | $0 | $0 |
| Net Income? | -$117.26M | -$83.58M | -$81.17M | -$58.03M | -$84.69M | -$26.51M | -$18.75M | -$19.17M | -$20.24M |
| EPS? | $-12.48 | $-9.37 | $-53.09 | $-227.58 | $-4.94 | $-41.10 | $-30.39 | $-30.57 | $-32.27 |
| Diluted EPS? | $-12.48 | $-9.37 | $-53.08 | $-227.42 | $-4.94 | $-41.10 | $-30.39 | $-30.57 | $-32.27 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality